A randomised trial of idarubicin dose escalation in consolidation therapy following intensive induction chemotherapy incorporating high dose cytarabine in patients with untreated adult acute myeloid leukaemia, to evaluate safety and improve remission rate.

DOI number 10.58109/gfyk-k522
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Kenneth Bradstock (Westmead Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 442 patients
  • Includes first Australian study conduceted in AML using dose escalation therapy
  • Also investigates use of antiemetics and oral mucositis medication
  • Dataset includes demographic data, diagnostic, treatment data, outcome data induction and consolidation treatment, including measurements for progression and clinical outcomes
  • Patients who underwent BMT were censored for this study

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)


ANZCTR Reference ACTRN12605000095662
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au